His scientific interests lie mostly in Rheumatoid arthritis, Internal medicine, Arthritis, Immunology and Rheumatology. His research integrates issues of Physical therapy, Connective tissue disease and Disease in his study of Rheumatoid arthritis. The various areas that Gerd R Burmester examines in his Physical therapy study include Alternative medicine, Evidence-based medicine, Family medicine and Intensive care medicine.
His Internal medicine research incorporates themes from Gastroenterology, Placebo and Surgery. His Arthritis research is multidisciplinary, incorporating elements of Porphyromonas gingivalis, Rheumatism and Randomized controlled trial. His Rheumatology research is multidisciplinary, incorporating perspectives in Osteoarthritis, High tibial osteotomy, Chondrocyte and Orthopedic surgery.
Gerd R Burmester mainly focuses on Internal medicine, Rheumatoid arthritis, Immunology, Rheumatology and Arthritis. His Internal medicine research includes elements of Gastroenterology, Placebo and Surgery. His Surgery study combines topics in areas such as Connective tissue disease and Infliximab.
His Rheumatoid arthritis research is multidisciplinary, incorporating elements of Physical therapy, Clinical trial and Disease. The study incorporates disciplines such as Psoriatic arthritis, Family medicine, Rheumatism, Ankylosing spondylitis and Severity of illness in addition to Rheumatology. His work in Synovitis and Antirheumatic Agents is related to Arthritis.
Gerd R Burmester focuses on Internal medicine, Rheumatoid arthritis, In patient, Sarilumab and Adalimumab. As a part of the same scientific study, Gerd R Burmester usually deals with the Internal medicine, concentrating on Gastroenterology and frequently concerns with Bone remodeling. His studies deal with areas such as Placebo, Methotrexate, Clinical endpoint and Arthritis as well as Rheumatoid arthritis.
His work on Synovitis as part of his general Arthritis study is frequently connected to GERD, thereby bridging the divide between different branches of science. His research in Rheumatology intersects with topics in Medical laboratory, Family medicine and Intensive care medicine. The concepts of his Adverse effect study are interwoven with issues in Oncology, Janus kinase inhibitor, Randomized controlled trial, Myocardial infarction and Filgotinib.
Internal medicine, Rheumatoid arthritis, Rheumatology, Intensive care medicine and Clinical trial are his primary areas of study. His work is connected to Adalimumab, Adverse effect, Psoriatic arthritis, Tocilizumab and Tofacitinib, as a part of Internal medicine. His studies in Rheumatoid arthritis integrate themes in fields like Methotrexate, Discontinuation, Arthritis, Placebo and Safety profile.
Gerd R Burmester frequently studies issues relating to Family medicine and Rheumatology. His work carried out in the field of Intensive care medicine brings together such families of science as High morbidity, Disease and Interstitial lung disease. In Disease, Gerd R Burmester works on issues like Epidemiology, which are connected to Translational science.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits.
Arthritis & Rheumatism (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch.
Annals of the Rheumatic Diseases (2014)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld.
Annals of the Rheumatic Diseases (2010)
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Thomas J Schnitzer;Gerd R Burmester;Eduardo Mysler;Marc C Hochberg.
The Lancet (2004)
Macrophages in rheumatoid arthritis
Raimund W Kinne;Rolf Bräuer;Bruno Stuhlmüller;Ernesta Palombo-Kinne.
Arthritis Research & Therapy (2000)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Christian E. Antoni;Arthur Kavanaugh;Bruce Kirkham;Zuhre Tutuncu.
Arthritis & Rheumatism (2005)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R Burmester;Ricardo Blanco;Christina Charles-Schoeman;Jürgen Wollenhaupt.
The Lancet (2013)
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Michael E. Farkouh;Howard Kirshner;Robert A. Harrington;Sean Ruland.
The Lancet (2004)
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus.
Marcus Odendahl;Annett Jacobi;Arne Hansen;Eugen Feist.
Journal of Immunology (2000)
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
Antonio Naranjo;Tuulikki Sokka;Miguel A. Descalzo;Jaime Calvo-Alén.
Arthritis Research & Therapy (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: